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Abstract
To date, at least 900 different microRNA (miRNA) genes have been discovered in the human genome. These short,
single-stranded RNA molecules originate from larger precursor molecules that fold to produce hairpin structures,
which are subsequently processed by ribonucleases Drosha/Pasha and Dicer to form mature miRNAs. MiRNAs play
role in the posttranscriptional regulation of about one third of human genes, mainly via degradation of target
mRNAs. Whereas the target mRNAs are often involved in the regulation of diverse physiological processes ranging
from developmental timing to apoptosis, miRNAs have a strong potential to regulate fundamental biological
processes also in the lung compartment. However, the knowledge of the role of miRNAs in physiological and
pathological conditions in the lung is still limited. This review, therefore, summarizes current knowledge of the
mechanism, function of miRNAs and their contribution to lung development and homeostasis. Besides the involve-
ment of miRNAs in pulmonary physiological conditions, there is evidence that abnormal miRNA expression may
lead to pathological processes and development of various pulmonary diseases. Next, the review describes current
state-of-art on the miRNA expression profiles in smoking-related diseases including lung cancerogenesis, in
immune system mediated pulmonary diseases and fibrotic processes in the lung. From the current research it is
evident that miRNAs may play role in the posttranscriptional regulation of key genes in human pulmonary
diseases. Further studies are, therefore, necessary to explore miRNA expression profiles and their association with
target mRNAs in human pulmonary diseases.
A. miRNA definition, biology and function
Discovery of microRNA (miRNA)
lin-4 was the first short non-coding RNA discovered in
1993 as a regulator of developmental timing in Caenor-
habditis elegans [1]. The first non-coding RNA identi-
fied in humans was let-7, which has been found
involved in the control of developmental timing in
humans and animals [2,3]. Soon it became evident that
these short non-coding RNAs are a part of much larger
class of non-coding RNAs and the term microRNA
(miRNA) was introduced [4]. To date, more than 900
miRNAs in Homo sapiens have been identified (940 in
miRBase v15).
Structure and function of miRNAs
MiRNAs are small non-coding RNAs ~22 nucleotides
(nt) long involved in the negative post-transcriptional
gene regulation via RNA interference mechanism [5,6].
The sequences of miRNAs are highly conserved among
plants-microorganisms-animals, suggesting that miRNAs
represent a relatively old and important regulatory
pathway [7]. MiRNAs belong to the most abundant
class of human gene regulators [8]: up to a third of the
human genes are regulated by miRNAs [9]. MiRNAs
are, therefore, key regulators of numerous genes in
biological processes ranging from developmental timing
to apoptosis [e.g. [10-14]]. It has been speculated that
miRNAs may be associated with the regulation of
almost every aspect of cell physiology [8].
miRNA biogenesis
MiRNA genes are localized in the non-coding regions or in
the introns of protein-coding genes in the genomic DNA.
The miRNA genes are much longer than biologically
active, mature miRNAs which originate through a multi-
step process [15] (Figure 1). Briefly, transcription by the
RNA polymerase II leads to hundred or thousand nucleo-
tides long primary miRNA transcripts (pri-miRNAs) [16].
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in the nucleus by the dsRNA-specific ribonuclease Drosha/
Pasha to 70 nucleotides long precursor miRNA (pre-
miRNA) [17] in a process known as “cropping” [18,19].
Pre-miRNAs are then actively transported from the
nucleus to the cytoplasm [20,21]. In the cytoplasm,
pre-miRNAs are subsequently cleaved by RNase III Dicer
into ~22-nt miRNA duplexes [17,20]. One strand of the
short-lived miRNA duplex is degraded ("passenger” strand,
miR*), whereas the other ("guide”, miR) strand is incorpo-
rated into the RNA-induced silencing complex (RISC) and
serves as a functional, mature miRNA [8]. Selection of the
“guide” strand is based on the base pairing stability of both
dsRNA ends [22,23].
Mechanism of miRNA action
Depending on the complementarity between miRNA and
3’ untranslated region (UTR) of target mRNA there are
two known mechanisms of miRNAs action on mRNAs: 1)
target mRNA degradation and 2) translational inhibition
with little or no influence on mRNA levels [24] (Figure 2).
Firstly, the deadenylation and subsequent degradation of
the target mRNA occurs when miRNA is near-perfectly
complementary with target mRNA [25,26]. A recent study
proved that mRNA degradation represents the major
mechanism of miRNA regulation [27]. The authors
showed that about 84% of all protein-coding mRNA
targets undergo degradation while recognized by their
cognate miRNA [27]. Secondly, the translational inhibition
Figure 1 miRNA biogenesis. MiRNAs are transcribed by RNA polymerase II from the genomic DNA as long (hundred or thousand nucleotides)
primary miRNA transcripts (pri-miRNAs). A local stem-loop structure of pri-miRNAs is then cleaved in the nucleus by the dsRNA-specific
ribonuclease Drosha/Pasha to produce a 70 nucleotides long precursor miRNA (pre-miRNA). Pre-miRNAs in form of hairpins are then actively
transported from the nucleus to the cytoplasm. In the cytoplasm, pre-miRNAs are subsequently cleaved by RNase III Dicer into ~22-nt miRNA
duplexes, consisting of the “guide” (miR) strand and the “passenger” (miR*) strand. The “passenger” strand is degraded, the “guide” strand is
incorporated into the RNA-induced silencing complex (RISC) and serves as a functional, mature miRNA, acting by two different mechanisms
according to the complementarity with the target mRNA. Adopted from Kim [15].
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target mRNA [28-30]. In light of the recent study by Guo
et al [27], this mechanism does not represent a predomi-
nant reason for reduced protein output.
Besides the complementarity between miRNA and
mRNA, several other factors may influence the miRNA
action such as impaired processing, methylation, gene
polymorphisms, gene amplification, deletion of Dicer,
translocations and others [31].
Targets of miRNAs
It is evident that single miRNAs may regulate transla-
tion of numerous downstream mRNAs and each mRNA
is likely to be regulated by several miRNAs simulta-
neously [30,32]. Thus, identification of miRNA target
genes has been a great challenge [33]. Numerous com-
putational algorithms [34-43] were established which
combined 5’ seed matches, thermodynamic stability and
conservation analysis in order to maximize specificity
when predicting mRNA targets [44] (Table 1). Neverthe-
less, various algorithms differ in the selection of mRNA
targets and simultaneous application of several algo-
rithms is, therefore, highly recommended. Nowadays,
many web-based applications [45-52] have been devel-
oped by combining existing prediction programs with
functional annotations associated to many miRNA, gene,
protein or biological pathway resources such as miR-
B a s e ,E n s e m b l ,S w i s s - P r o t ,U C S Cg e n o m eb r o w s e r ,
KEGG pathway and other databases [44] (Table 2).
However, because of high similarities in miRNA
sequences, computational algorithms may predict a large
number of putative miRNA binding sites on mRNA tar-
gets [33]. Thus, experimental validation in biological sys-
tem is fundamental to complete the target prediction
Figure 2 Mechanism of miRNA action on target mRNA. According to the complementarity between miRNA and 3’ untranslated region (UTR)
of target mRNA, there are two mechanisms of miRNA action: (A) when miRNA is near-perfectly complementary with target mRNA,
deadenylation and subsequent degradation of the target mRNA occurs (major mechanism of miRNA action); (B) when miRNA is only partially
complementary to its target mRNA, translational inhibition occurs. Adopted from Brodersen et al [24].
Table 1 Computational algorithms for miRNA target
prediction
Algorithm Web link References
miRanda http://www.microrna.org [34]
TargetScan http://genes.mit.edu/targetscan [35]
TargetScanS http://genes.mit.edu/targetscan [36]
PicTar http://pictar.mdc-berlin.de [37]
DIANA-
microT
http://diana.pcbi.upenn.edu/cgi-bin/micro_t.
cgi
[38]
ElMMo http://www.mirz.unibas.ch/ElMMo2/ [39]
MirTarget2 http://mirdb.org [40]
miTarget http://cbit.snu.ac.kr/~miTarget/ [41]
rna22 http://cbcsrv.watson.ibm.com/rna22.html [42]
RNAhybrid http://bibiserv.techfak.uni-bielefeld.de/
rnahybrid
[43]
Adopted from Min et al [44].
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listed in Table 3. Of these, antagomir studies or immuno-
precipitation of Ago-bound mRNAs have been specifically
developed for miRNA-mRNA studies. Antagomirs repre-
sent a novel class of chemically engineered oligonucleo-
tides used to silence endogenous microRNAs [64,65].
Immunoprecipitation is then based on the observation
that each member of the Argonaute (Ago) protein family
(catalytic components of the RNA-induced silencing com-
plex) can bind to miRNAs and to partially complementary
sequences in the 3’-UTR of specific target mRNAs. Thus,
using highly specific monoclonal antibodies against mem-
bers of the Ago protein family, Ago-bound mRNAs can be
co-immunoprecipitated [66,67].
B. miRNA in pulmonary physiology and pathology
Role of miRNAs in the lung
The lung has a very specific miRNA expression profile,
highly conserved across mammalian species [68,69].
H o w e v e r ,t h ek n o w l e d g eo ft h er o l eo fm i R N A si n
physiological and pathological conditions in the lung
compartment is still limited and it is based mainly on
the studies in animal models. MiRNAs have been shown
to be involved in 1) the lung development and homeos-
tasis, 2) in inflammation and viral infections and
3) miRNA deregulation may contribute to several pul-
monary diseases (Figure 3). Hereby, we summarize the
knowledge of the involvement of miRNAs in the lung
and current information on their posttranscriptional
regulation ongoing in the lung compartment. Besides
pathology we pay attention also to physiological lung
because understanding miRNA function in normal con-
dition is prerequisite to description of its involvement in
disease.
MiRNAs in the lung in physiological condition
Homeostasis and lung development
Several miRNAs such as miR-155, miR-26a, let-7,
miR-29, miR-15/miR-16, miR-223, miR-146a/b and the
miR-17-92 cluster have been shown to be involved in
homeostasis and in the lung development (Table 4). The
pulmonary role of miR-155 was studied in murine lung,
where it has been shown that miR-155 is crucially
involved in the differentiation of naive T-cells into Th1
and Th2 cells [70,71]. Mice deficient in bic/miR-155
became immunodeficient and displayed increased lung
remodelling, higher bronchoalveolar leukocytes and
impaired T- and B-cell responses to inflammatory sti-
muli [70]. Another member of miRNA family, miR-26a,
has been shown to be selectively expressed in the bron-
chial and alveolar epithelial cells in murine lung [72].
Target mRNA of miR-26a is the transcription factor
SMAD1, which is involved in the regulation of bone
morphogenic protein signalling during lung develop-
ment and pulmonary vascular remodelling [73,74].
Thus, miR-26a might be important in controlling essen-
tial developmental and physiological events in the lung
[75]. Also the miR-17-92 cluster is believed to regulate
the lung development because its expression is high in
embryonic development and steadily declines through
development into adulthood [76]. Mice deficient in the
miR-17-92 cluster died shortly after birth and lung
hypoplasia/ventricular septal defects were demonstrated;
moreover the absence of the miR-17-92 cluster let to
upregulation of the pro-apoptotic protein Bim and inhi-
bition of B-cell development [77]. On the other side, the
overexpression of the miR-17-92 cluster in murine mod-
els resulted in an abnormal phenotype manifested by
absence of terminal air sacs, which were replaced by
highly proliferative, undifferentiated pulmonary epithe-
lium [76]. Other miRNAs found to be involved in the
pulmonary homeostasis are members of let-7 family
[78], miR-29 [79], miR-15 and miR-16 [80,81], which
Table 2 Methods with extended features for miRNA
target prediction
Name Web link References
GOmir http://www.bioacademy.gr/bioinformatics/
projects/GOmir
[45]
miRDB http://mirdb.org [46]
miRecords http://miRecords.umn.edu/miRecords [47]
miRGator http://genome.ewha.ac.kr/miRGator [48]
miRNAMap http://miRNAMap.mbc.nctu.edu.tw [49]
mirZ http://www.mirz.unibas.ch [50]
MMIA http://156.56.93.156/~MMIA/mmia_main.html [51]
TarBase5.0 http://diana.cslab.ece.ntua.gr/tarbase [52]
Adopted from Min et al [44].
Table 3 Experimental methods to check the functional
interaction between miRNA and target mRNA
Method
Selected
references
Luciferase reporter assay [53]
Northern blot analysis [54]
Quantitative real-time PCR [55]
Ribonuclease protection assay [56]
in situ hybridization [57],[58]
miRNA mimics [59]
Western blot [60]
Immunocytochemistry [61]
Bead-based flow cytometry method [62]
Suppression of miRNA expression in cells by anti-
sense locked-nucleic acid oligonucleotides
[63]
Antagomir assays [64],[65]
Immunoprecipitation of Ago-bound mRNAs [66],[67]
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another miRNA, miR-223, has been shown to be crucial
for normal granulocyte development and function in the
lung [82]. MiR-223 mutant mice spontaneously devel-
oped neutrophilic lung inflammation with tissue
destruction after endotoxin challenge [82].
Control of pulmonary inflammation and viral infections
Two miRNAs, miR-146a and miR-146b, have been
shown to play central role in the negative feedback reg-
ulation of IL-1b-induced inflammation; the mechanism
is down-regulation of two proteins IRAK1 and TRAF6
involved in Toll/interleukin-1 receptor (TIR) signalling
[83,84]. Also other miRNAs have been shown to regu-
late the inflammation in mouse lung exposed to
aerosolized lipopolysaccharide (LPS): miR-21,- 25,- 27b,
-100,- 140,- 142-3p,- 181c,- 187,- 194,- 214,- 223 and
-224 [72]. Increase in these miRNAs correlated with the
downregulation of pro-inflammatory cytokine produc-
tion such as TNFa [72]. The deregulation of miR-155,
the miR-17-92 cluster and miR-223, miRNAs involved in
lung development and homeostasis, resulted in the
uncontrolled lung inflammation in murine models
[70,77,82].
Based on the studies in murine models, there is evi-
dence that miRNA expression may influence also the
course of pulmonary viral infections [85,86]. MiR-200a
and miR-223 were detected in lethal influenza virus
infection presumably contributing to the extreme
Figure 3 Involvement of miRNAs in physiological and pathological processes in lung. The scheme shows several miRNAs involved in
physiological and pathological processes in lung. There has been shown that numerous miRNAs are implicated in maintaining lung homeostasis
and development. When deregulation of these miRNAs occurs, pathological processes turn up and may lead to the development of pulmonary
diseases.
Table 4 MiRNAs involved in physiological processes in the lung
miRNA Function (A animal studies, H human studies) References
miR-17-92 cluster important in lung development and homeostasis (A) [69],[76,[77]
miR-155 important for normal lung airway remodelling (A) [70]
alteration of T-cell differentiation (A) [71]
miR-26a highly expressed within bronchial and alveolar epithelial cells, important for lung development (H) [75]
let-7 highly expressed in normal lung tissue, functions as a tumor suppressor in lung cells (H) [78]
miR-29 functions as tumor suppressor in lung cells (H) [79]
miR-15, miR-16 function as tumor suppressor genes (H) [80],[81]
miR-223 control of granulocyte development and function (A) [82]
miR-146a/b central to the negative feedback regulation of IL-1b-induced inflammation (H) [83],[84]
miR-200a, miR-223 contribution to the extreme virulence of the r1918 influenza virus (A) [85]
miR-17 family, miR-574-5p, miR-214 upregulated at the onset of SARS infection (A, H) [86]
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family, miR-574-5p and miR-214 were upregulated at
the onset of SARS infection: these miRNAs may help
the virus to evade the host immune system and are
responsible for effective transmission at the initial stage
of viral infection [86].
Deregulation of miRNAs leads to development of
pulmonary diseases
There is evidence that upregulation or downregulation
of miRNAs is critical for the lung development/homeos-
tasis and thus may contribute to development of
pathological pulmonary conditions, namely to smoking-
related diseases including lung cancerogenesis, fibrosis,
and other immune-mediated disorders including allergy
(Table 5).
Immune-mediated lung diseases
Recent studies have implicated the miRNAs in the
pathogenesis of immune system mediated pulmonary
diseases. Tan and colleagues [87] described that a single
nucleotide polymorphism in the 3’UTR of HLA-G, a
known asthma-susceptibility gene, disrupts the binding
sites of three miRNAs (miR-148a, miR-148b, miR-152)
targeting this gene. Thus, it is likely that the association
of the HLA-G gene to asthma-susceptibility may be due
to the allele-specific regulation of this gene by miRNAs
[87]. MiR-21 is a further miRNA crucially involved in
allergic lung inflammation. Its molecular target is
IL-12p35, a cytokine contributing to polarization of Th
cells toward Th2 cells [88]. MiR-126 is another miRNA
found to be involved in the pathogenesis of allergic air-
ways disease [89]. The blockade of miR-126 suppressed
the asthmatic phenotype leading to diminished Th2
responses, suppression of inflammation, reduced airways
hyperresponsiveness, inhibition of eosinophil recruit-
ment, and lower mucus hypersecretion [89]. In bron-
chial epithelial cells stimulated with IL-4 and TNFa,
let-7, miR-29a and miR-155 have been involved in the
regulation of allergic inflammation [90]. Multiple
members of let-7 family were also found upregulated in
experimental asthma model and the pro-inflammatory
role of let-7 miRNAs on the allergic cytokine expression
was confirmed [91]. Another study showed that expression
of RhoA in bronchial smooth muscle cells (BSMCs), a new
target for asthma therapy, is negatively regulated by
miR-133a [92]. The same group later revealed that IL-13
is capable of reducing the miR-133a expression in BSMCs
and that the miR-133a downregulation causes an
Table 5 MiRNAs involved in pathological processes in the lung
miRNA Function (A animal studies, H human studies) References
miR-155, miR-17-92 cluster deregulation results in uncontrolled inflammation (A) [70],[71],[77]
miR-21, miR-27b, miR-100, miR-181c, miR-223, miR-224 increased following exposure to LPS (A) [72]
miR-155 overexpressed in solid tumors, inhibition of tumor suppressor genes (A, H) [81]
miR-223 impaired granulocyte function, regulator of granulocyte production
and inflammatory response (A)
[82]
miR-148a/b, miR-152 allele-specific regulation of asthma susceptibility HLA-G gene (H) [87]
miR-21 key role in asthma (A) [88]
overexpressed in solid malignancies (A, H) [103]
up-regulated in bleomycin-induced fibrosis and IPF (A, H) [110]
miR-126 suppression of the asthmatic phenotype by blockade of miR-126 (A) [89]
downregulated in cystic fibrosis airway
epithelial cells (H)
[111]
let-7, miR-29a, miR-155 regulation of allergic inflammation in bronchial epithelial cells (A, H) [90]
let-7 pro-inflammatory effect in experimental asthma (A) [91]
role in lung cancer progression (H) [99]
miR-133a regulator of expression of RhoA, target for asthma therapy (A, H) [92],[93]
miR-146a reduced expression in COPD fibroblasts (H) [95]
miR-218, miR-15a, miR-199b, miR-125a/b, miR-294 deregulated due to smoking (A, H) [96,97]
miR-218 tumor suppressor in non-small cell lung cancer (H) [98]
miR-17-92 cluster overexpressed in lung cancers (H) [102]
miR-34 regulation of apoptosis in lung cancer cells (H) [105-107]
miR-210 overexpressed in lung cancer (H) [108]
let-7d pro-fibrotic effect in pulmonary fibrosis (A, H) [109]
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mentation of the contraction [93].
Smoking-related lung diseases
Lung cancer and chronic obstructive pulmonary disease
(COPD) share a common environmental risk factor in
cigarette smoke exposure [94]. Although extensive stu-
dies of the involvement of miRNAs in lung cancer have
been performed, there are only few reports focused on
t h er o l eo fm i R N A si nC O P D .R e c e n ts t u d yo nf i b r o -
blasts from COPD subjects stimulated in vitro with
pro-inflammatory cytokines released less miR-146a than
smokers without COPD [95]. The reduced miR-146a
expression resulted in prolonged mRNA half-life of
cyclooxygenase-2, thus increasing prostaglandin E2 in
fibroblasts from COPD subjects [95]. There is evidence
that smoking has influence also on other miRNAs.
Expression profiling study in the rats exposed to envir-
onmental cigarette smoke revealed 24 downregulated
miRNAs (especially let-7 family, miR-10, -26, -30, -34,
-99, -122, -123, -124, -125, -140, -145, -146, -191, -192,
-219, -222, and -223) when compared to control group
[96]. MiR-294, a known inhibitor of transcriptional
repressor genes, was the only miRNA upregulated in
smoke-exposed rats [96]. In another study, bronchial
airway epithelial cells from current and never smokers
differed in the expression of 28 miRNAs (especially
miR-218, miR-15a, miR-199b, miR-125a/b, miR-294)i n
comparison to smokers, whereas the majority of deregu-
lated miRNAs were downregulated in smokers [97].
Similar observation was observed in lung squamous cell
carcinoma, where downregulation of miR-218 was asso-
ciated with a history of cigarette smoking [98].
However, the majority of miRNA studies in smoking-
related diseases are focused on the role of miRNAs in
lung cancer. Altered expression of miR-155 and let-7
has been reported in lung adenocarcinoma and expres-
sion of let-7 related to patient survival [99]. Moreover, it
has been shown that let-7 may also play a role in lung
cancer progression [99-101]. Further, increased expres-
sion of the miR-17-92 cluster has also been detected in
lung cancer [102]. Another miRNAs involved in lung
cancerogenesis are miR-21 and miR-34 families. MiR-21
was shown to regulate multiple tumor/metastasis sup-
pressor genes in lung solid tumors [103]. MiR-34a/b/c
have been identified to be a component of the p53
tumor suppressor network: p53 upregulates in response
to DNA damage the members of miR-34 family [104],
thus regulating genes involved in the cell cycle and
apoptosis [105-107]. Furthermore, miR-210 has been
overexpressed in late stages of lung cancer, thus
mediated mitochondrial alterations associated with mod-
ulation of hypoxia-inducible factor-1 activity [108]. Next,
miR-218 was identified as a putative tumor suppressor
in non-small cell lung cancer [98].
Other lung diseases
Recently, it was reported that miRNAs may play pivotal
regulatory role also in the fibrotic processes ongoing in
the lung: the downregulation of let-7 d in idiopathic pul-
monary fibrosis (IPF) resulted in the pro-fibrotic effects
[109]. Also, upregulation of miR-21 was reported in the
lungs of IPF patients and in the murine lungs with bleo-
mycin-induced fibrosis, whereas miR-21 expression was
enhanced by pro-fibrotic TGF-b1 [110]. Another disease
associated with miRNA change was cystic fibrosis.
Downregulation of miR-126 was detected in cystic fibro-
sis bronchial epithelial cells and its expression correlated
with upregulation of TOM1 mRNA both in vitro and in
vivo [111]. TOM1, a miR-126 target, was reported to be
involved in the regulation of innate immune responses
through its involvement in the TLR2/4 and IL-1b and
TNF-a-induced signalling pathways [111].
Conclusion
Small non-coding RNAs (miRNAs) play pivotal role in
the posttranscriptional regulation of numerous human
genes, mainly via degradation of target mRNAs. There is
evidence that the lung has a very specific miRNA
expression profile undergoing changes during the lung
development. Studies namely in animal models have
provided evidence that miRNAs participate in lung
homeostasis and play pivotal role also in the control of
pulmonary inflammation and viral infections. Recent
studies showed evidence that upregulated or downregu-
lated expression of various miRNAs play an active role
in the pathogenesis of pulmonary diseases. Specific
miRNA expression profiles were characterized for smok-
ing related-diseases including COPD and lung cancer,
immune-mediated pulmonary diseases and pulmonary
fibrosis. Moreover, several miRNAs crucial for lung
development and homeostasis such as let-7, miR-155 or
miR-19-72 cluster have been identified to be deregulated
in pulmonary allergy, asthma or lung cancer. The
knowledge of altered miRNA expression profiles in dis-
eased lung may thus offer new insights in the biology of
pulmonary diseases. Moreover, miRNAs may represent
attractive novel diagnostic biomarkers mainly due to
their higher stability when compared to mRNAs [112]
and could potentially provide possibilities for therapeutic
intervention [31,113,114].
Acknowledgements
Funding was obtained from the Czech Ministry of Health (IGA MZ CR NT/
11117-6, IGA MZ CR NS/10267-3, IGA MZ CR NS/10260-3) and in part by the
Internal Grant Agency of Palacky University (IGA PU project SV LF_2010_008).
The authors declare no conflicting financial interests.
Authors’ contributions
All authors wrote and revised the manuscript, and approved the final
version.
Tomankova et al. Respiratory Research 2010, 11:159
http://respiratory-research.com/content/11/1/159
Page 7 of 10Competing interests
The authors declare that they have no competing interests.
Received: 15 August 2010 Accepted: 23 November 2010
Published: 23 November 2010
References
1. Lee RC, Feinbaum RL, Ambros V: The C. elegans heterochronic gene lin-4
encodes small RNAs with antisense complementarity to lin-14. Cell 1993,
75:843-854.
2. Hutvágner G, McLachlan J, Pasquinelli AE, Bálint E, Tuschl T, Zamore PD: A
cellular function for the RNA-interference enzyme Dicer in the
maturation of the let-7 small temporal RNA. Science 2001, 293:834-838.
3. Rougvie AE: Control of developmental timing in animals. Nat Rev Genet
2001, 2:690-701.
4. Ruvkun G: Molecular biology. Glimpses of a tiny RNA world. Science 2001,
26:797-799.
5. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function.
Cell 2004, 116:281-297.
6. He L, Hannon GJ: MicroRNAs: small RNAs with a big role in gene
regulation. Nat Rev Genet 2004, 5:522-531.
7. Grosshans H, Slack FJ: Micro-RNAs: small is plentiful. J Cell Biol 2002,
156:17-21.
8. Sonkoly E, Pivarcsi A: Advances in microRNAs: implications for immunity
and inflammatory diseases. J Cell Mol Med 2009, 13:24-38.
9. Mattes J, Collison A, Foster PS: Emerging role of microRNAs in disease
pathogenesis and strategies for therapeutic modulation. Curr Opin Mol
Ther 2008, 10:150-157.
10. Wang Y, Stricker HM, Gou D, Liu L: MicroRNA: past and present. Front
Biosci 2007, 12:2316-2329.
11. Boehm M, Slack F: A developmental timing microRNA and its target
regulate life span in C. elegans. Science 2005, 310:1954-1957.
12. Sokol NS, Ambros V: Mesodermally expressed Drosophila microRNA-1 is
regulated by Twist and is required in muscles during larval growth.
Genes Dev 2005, 19:2343-2354.
13. Xu P, Guo M, Hay BA: MicroRNAs and the regulation of cell death. Trends
Genet 2004, 20:617-624.
14. Esau C, Kang X, Peralta E, Hanson E, Marcusson EG, Ravichandran LV, Sun Y,
Koo S, Perera RJ, Jain R, Dean NM, Freier SM, Bennett CF, Lollo B, Griffey R:
MicroRNA-143 regulates adipocyte differentiation. J Biol Chem 2004,
279:52361-52365.
15. Kim VN: MicroRNA biogenesis: coordinated cropping and dicing. Nature
Reviews Molecular Cell Biology 2005, 6:376-385.
16. Lee Y, Jeon K, Lee JT, Kim S, Kim VN: MicroRNA maturation: stepwise
processing and subcellular localization. EMBO J 2002, 21:4663-4670.
17. Lee Y, Ahn C, Han J, Choi H, Kim J, Yim J, Lee J, Provost P, Rådmark O,
Kim S, Kim VN: The nuclear RNase III Drosha initiates microRNA
processing. Nature 2003, 425:415-419.
18. Smalheiser NR: EST analyses predict the existence of a population of
chimeric microRNA precursor-mRNA transcripts expressed in normal
human and mouse tissues. Genome Biol 2003, 4:403.
19. Cai X, Hagedorn CH, Cullen BR: Human microRNAs are processed from
capped, polyadenylated transcripts that can also function as mRNAs.
RNA 2004, 10:1957-1966.
20. Yi R, Qin Y, Macara IG, Cullen BR: Exportin-5 mediates the nuclear export
of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011-3016.
21. Lund E, Güttinger S, Calado A, Dahlberg JE, Kutay U: Nuclear export of
microRNA precursors. Science 2004, 303:95-98.
22. Schwarz DS, Hutvágner G, Du T, Xu Z, Aronin N, Zamore PD: Asymmetry in
the assembly of the RNAi enzyme complex. Cell 2003, 115:199-208.
23. Khvorova A, Reynolds A, Jayasena SD: Functional siRNAs and miRNAs
exhibit strand bias. Cell 2003, 115:209-216.
24. Brodersen P, Voinnet O: Revisiting the principles of microRNA target
recognition and mode of action. Nature Reviews Molecular Cell Biology
2009, 10:141-148.
25. Giraldez AJ, Mishima Y, Rihel J, Grocock RJ, Van Dongen S, Inoue K,
Enright AJ, Schier AF: Zebrafish MiR-430 promotes deadenylation and
clearance of maternal mRNAs. Science 2006, 312:75-79.
26. Wu L, Fan J, Belasco JG: MicroRNAs direct rapid deadenylation of mRNA.
Proc Natl Acad Sci USA 2006, 103:4034-4039.
27. Guo H, Ingolia NT, Weissman JS, Bartel DP: Mammalian microRNAs
predominantly act to decrease target mRNA levels. Nature 2010,
466:835-840.
28. Wightman B, Ha I, Ruvkun G: Posttranscriptional regulation of the
heterochronic gene lin-14 by lin-4 mediates temporal pattern formation
in C. elegans. Cell 1993, 75:855-862.
29. Olsen PH, Ambros V: The lin-4 regulatory RNA controls developmental
timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis
after the initiation of translation. Dev Biol 1999, 216:671-680.
30. Doench JG, Sharp PA: Specificity of microRNA target selection in
translational repression. Genes Dev 2004, 18:504-511.
31. Nana-Sinkam SP, Hunter MG, Nuovo GJ, Schmittgen TD, Gelinas R, Galas D,
Marsh CB: Integrating the MicroRNome into the study of lung disease.
Am J Respir Crit Care Med 2009, 179:4-10.
32. Lim LP, Lau NC, Garrett-Engele P, Grimson A, Schelter JM, Castle J,
Bartel DP, Linsley PS, Johnson JM: Microarray analysis shows that some
microRNAs downregulate large numbers of target mRNAs. Nature 2005,
433:769-773.
33. Kuhn DE, Martin MM, Feldman DS, Terry AV Jr, Nuovo GJ, Elton TS:
Experimental validation of miRNA targets. Methods 2008, 44:47-54.
34. Enright AJ, John B, Gaul U, Tuschl T, Sander C, Marks DS: MicroRNA targets
in Drosophila. Genome Biol 2003, 5:R1.
35. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of
mammalian microRNA targets. Cell 2003, 115:787-798.
36. Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by
adenosines, indicates that thousands of human genes are microRNA
targets. Cell 2005, 120:15-20.
37. Grun D, Wang YL, Langenberger D, Gunsalus KC, Rajewsky N: MicroRNA
target predictions across seven Drosophila species and comparison to
mammalian targets. PLoS Comput Biol 2005, 1:e13.
38. Kiriakidou M, Nelson PT, Kouranov A, Fitziev P, Bouyioukos C, Mourelatos Z,
Hatzigeorgiou A: A combined computational-experimental approach
predicts human microRNA targets. Genes Dev 2004, 18:1165-1178.
39. Gaidatzis D, van Nimwegen E, Hausser J, Zavolan M: Inference of miRNA
targets using evolutionary conservation and pathway analysis. BMC
Bioinformatics 2007, 8:69.
40. Wang X, El Naqa IM: Prediction of both conserved and nonconserved
microRNA targets in animals. Bioinformatics 2008, 24:325-332.
41. Kim SK, Nam JW, Rhee JK, Lee WJ, Zhang BT: miTarget: microRNA target-
gene prediction using a support vector machine. BMC Bioinformatics
2006, 7:411.
42. Miranda KC, Huynh T, Tay Y, Ang YS, Tam WL, Thomson AM, Lim B,
Rigoutsos I: A pattern-based method for the identification of microRNA
binding sites and their corresponding heteroduplexes. Cell 2006,
126:1203-1217.
43. Rehmsmeier M, Steffen P, Hochsmann M, Giegerich R: Fast and effective
prediction of microRNA/target duplexes. RNA 2004, 10:1507-1517.
44. Min H, Yoon S: Got target? Computational methods for microRNA target
prediction and their extension. Exp Mol Med 2010, 42:233-244.
45. Roubelakis MG, Zotos P, Papachristoudis G, Michalopoulos I, Pappa KI,
Anagnou NP, Kossida S: Human microRNA target analysis and gene
ontology clustering by GOmir, a novel stand-alone application. BMC
Bioinformatics 2009, 10:S20.
46. Wang X: miRDB: A microRNA target prediction and functional annotation
database with a wiki interface. RNA 2008, 14:1012-1017.
47. Xiao F, Zuo Z, Cai G, Kang S, Gao X, Li T: MiRecords: an integrated
resource for microRNA-target interactions. Nucleic Acids Res 2009, 37:
D105-110.
48. Nam S, Kim B, Shin S, Lee S: miRGator: an integrated system for
functional annotation of microRNAs. Nucleic Acid Res 2008, 36:
D159-164.
49. Hsu SD, Chu CH, Tsou AP, Chen SJ, Chen HC, Hsu PW, Wong YH, Chen YH,
Chen GH, Huang HD: miRNAMap 2.0: genomic maps of microRNAs in
metazoan genomes. Nucleic Acids Res 2008, 36:D165-169.
50. Hausser J, Berninger P, Rodak C, Jantscher Y, Wirth S, Zavolan M: MirZ: an
integrated microRNA expression atlas and target prediction resource.
Nucleic Acids Res 2009, 36:W266-272.
51. Nam S, Li M, Choi K, Balch C, Kim S, Nephew KP: MicroRNA and mRNA
integrated analysis (MMIA): a web tool for examining biological
functions of microRNA expression. Nucleic Acids Res 2009, 37:W356-362.
Tomankova et al. Respiratory Research 2010, 11:159
http://respiratory-research.com/content/11/1/159
Page 8 of 1052. Papadopoulos GL, Reczko M, Simossis VA, Sethupathy P, Hatzigeorgiou AG:
The database of experimentally supported targets: a functional update
of TarBase. Nucleic Acids Res 2009, 37:D155-158.
53. Martin MM, Lee EJ, Buckenberger JA, Schmittgen TD, Elton TS: MicroRNA-
155 regulates human angiotensin II type 1 receptor expression in
fibroblasts. J Biol Chem 2006, 281:18277-18284.
54. Norden-Krichmar TM, Holtz J, Pasquinelli AE, Gaasterland T: Computational
prediction and experimental validation of Ciona intestinalis microRNA
genes. BMC Genomics 2007, 8:445.
55. Hurteau GJ, Spivack SD, Brock GJ: Potential mRNA degradation targets of
hsa-miR-200c, identified using informatics and qRT-PCR. Cell Cycle 2006,
5:1951-1956.
56. Gu Z, Eleswarapu S, Jiang H: Identification and characterization of
microRNAs from the bovine adipose tissue and mammary gland. FEBS
Lett 2007, 581:981-988.
57. Martin MM, Buckenberger JA, Jiang J, Malana GE, Nuovo GJ, Chotani M,
Feldman DS, Schmittgen TD, Elton TS: The human angiotensin II type 1
receptor +1166 A/C polymorphism attenuates microrna-155 binding.
J Biol Chem 2007, 282:24262-24269.
58. Wheeler G, Valoczi A, Havelda Z, Dalmay T: In situ detection of animal and
plant microRNAs. DNA Cell Biol 2007, 26:251-255.
59. Wang F, Xue X, Wei J, An Y, Yao J, Cai H, Wu J, Dai C, Qian Z, Xu Z, Miao Y:
hsa-miR-520 h downregulates ABCG2 in pancreatic cancer cells to
inhibit migration, invasion, and side populations. Br J Cancer 2010,
103:567-574.
60. Li J, Xia W, Huang B, Chen L, Su X, Li S, Wang F, Ding H, Shao N: A
strategy to rapidly identify the functional targets of microRNAs by
combining bioinformatics and mRNA cytoplasmic/nucleic ratios in
culture cells. FEBS Lett 2010, 584:3198-3202.
61. Ozen M, Creighton CJ, Ozdemir M, Ittmann M: Widespread deregulation of
microRNA expression in human prostate cancer. Oncogene 2008,
27:1788-1793.
62. Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-
Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR,
Golub TR: MicroRNA expression profiles classify human cancers. Nature
2005, 435:834-838.
63. Lecellier CH, Dunoyer P, Arar K, Lehmann-Che J, Eyquem S, Himber C,
Saïb A, Voinnet O: A cellular microRNA mediates antiviral defense in
human cells. Science 2005, 308:557-560.
64. Fontana L, Fiori ME, Albini S, Cifaldi L, Giovinazzi S, Forloni M, Boldrini R,
Donfrancesco A, Federici V, Giacomini P, Peschle C, Fruci D: Antagomir-17-
5p abolishes the growth of therapy-resistant neuroblastoma through
p21 and BIM. PLoS One 2008, 3:e2236.
65. Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M,
Stoffel M: Silencing of microRNAs in vivo with ‘antagomirs’. Nature 2005,
438:685-689.
66. Beitzinger M, Peters L, Zhu JY, Kremmer E, Meister G: Identification of
human microRNA targets from isolated argonaute protein complexes.
RNA Biol 2007, 4:76-84.
67. Easow G, Teleman AA, Cohen SM: Isolation of microRNA targets by
miRNP immunopurification. RNA 2007, 13:1198-1204.
68. Williams AE, Moschos SA, Perry MM, Barnes PJ, Lindsay MA: Maternally
imprinted microRNAs are differentially expressed during mouse and
human lung development. Dev Dyn 2007, 236:572-580.
69. Williams AE, Perry MM, Moschos SA, Lindsay MA: microRNA expression in
the aging mouse lung. BMC Genomics 2007, 8:172.
70. Rodriguez A, Vigorito E, Clare S, Warren MV, Couttet P, Soond DR, van
Dongen S, Grocock RJ, Das PP, Miska EA, Vetrie D, Okkenhaug K, Enright AJ,
Dougan G, Turner M, Bradley A: Requirement of bic/microRNA-155 for
normal immune function. Science 2007, 316:608-611.
71. Banerjee A, Schambach F, DeJong CS, Hammond SM, Reiner SL: Micro-
RNA-155 inhibits IFN-gamma signaling in CD4+ T cells. Eur J Immunol
2010, 40:225-231.
72. Moschos SA, Williams AE, Perry MM, Birrell MA, Belvisi MG, Lindsay MA:
Expression profiling in vivo demonstrates rapid changes in lung
microRNA levels following lipopolysaccharide-induced inflammation but
not in the anti-inflammatory action of glucocorticoids. BMC Genomics
2007, 8:240.
73. Chen C, Chen H, Sun J, Bringas P Jr, Chen Y, Warburton D, Shi W: Smad1
expression and function during mouse embryonic lung branching
morphogenesis. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1033-9.
74. Frank DB, Abtahi A, Yamaguchi DJ, Manning S, Shyr Y, Pozzi A, Baldwin HS,
Johnson JE, de Caestecker MP: Bone morphogenetic protein 4 promotes
pulmonary vascular remodeling in hypoxic pulmonary hypertension. Circ
Res 2005, 97:496-504.
75. Williams AE, Larner-Svensson H, Perry MM, Campbell GA, Herrick SE,
Adcock IM, Erjefalt JS, Chung KF, Lindsay MA: MicroRNA expression
profiling in mild asthmatic human airways and effect of corticosteroid
therapy. PloS One 2009, 4:e5889.
76. Lu Y, Thomson JM, Wong HY, Hammond SM, Hogan BL: Transgenic over-
expression of the microRNA miR-17-92 cluster promotes proliferation
and inhibits differentiation of lung epithelial progenitor cells. Dev Biol
2007, 310:442-453.
77. Ventura A, Young AG, Winslow MM, Lintault L, Meissner A, Erkeland SJ,
Newman J, Bronson RT, Crowley D, Stone JR, Jaenisch R, Sharp PA, Jacks T:
Targeted deletion reveals essential and overlapping functions of the
miR-17 through 92 family of miRNA clusters. Cell 2008, 132:875-886.
78. Johnson CD, Esquela-Kerscher A, Stefani G, Byrom M, Kelnar K,
Ovcharenko D, Wilson M, Wang X, Shelton J, Shingara J, Chin L, Brown D,
Slack FJ: The let-7 microRNA represses cell proliferation pathways in
human cells. Cancer Res 2007, 67:7713-7722.
79. Fabbri M, Garzon R, Cimmino A, Liu Z, Zanesi N, Callegari E, Liu S, Alder H,
Costinean S, Fernandez-Cymering C, Volinia S, Guler G, Morrison CD,
Chan KK, Marcucci G, Calin GA, Huebner K, Croce CM: MicroRNA-29 family
reverts aberrant methylation in lung cancer by targeting DNA
methyltransferases 3A and 3B. Proc Natl Acad Sci USA 2007,
104:15805-15810.
80. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev
Cancer 2006, 6:857-866.
81. Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R,
Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A,
Vecchione A, Negrini M, Harris CC, Croce CM: A microRNA expression
signature of human solid tumors defines cancer gene targets. Proc Natl
Acad Sci USA 2006, 103:2257-2261.
82. Johnnidis JB, Harris MH, Wheeler RT, Stehling-Sun S, Lam MH, Kirak O,
Brummelkamp TR, Fleming MD, Camargo FD: Regulation of progenitor cell
proliferation and granulocyte function by microRNA-223. Nature 2008,
451:1125-1129.
83. Taganov KD, Boldin MP, Chang KJ, Baltimore D: NF-kappaB-dependent
induction of microRNA miR-146, an inhibitor targeted to signaling
proteins of innate immune responses. Proc Natl Acad Sci USA 2006,
103:12481-12486.
84. Perry MM, Moschos SA, Williams AE, Shepherd NJ, Larner-Svensson HM,
Lindsay MA: Rapid changes in microRNA-146a expression negatively
regulate the IL-1beta-induced inflammatory response in human lung
alveolar epithelial cells. J Immunol 2008, 180:5689-5698.
85. Li Y, Chan EY, Li J, Ni C, Peng X, Rosenzweig E, Tumpey TM, Katze MG:
MicroRNA expression and virulence in pandemic influenza virus-infected
mice. J Virol 2010, 84:3023-3032.
86. Mallick B, Ghosh Z, Chakrabarti J: MicroRNome analysis unravels the
molecular basis of SARS infection in bronchoalveolar stem cells. PLoS
One 2009, 4:e7837.
87. Tan Z, Randall G, Fan J, Camoretti-Mercado B, Brockman-Schneider R, Pan L,
Solway J, Gern JE, Lemanske RF, Nicolae D, Ober C: Allele-specific
targeting of microRNAs to HLA-G and risk of asthma. Am J Hum Genet
2007, 81:829-834.
88. Lu TX, Munitz A, Rothenberg ME: MicroRNA-21 is up-regulated in allergic
airway inflammation and regulates IL-12p35 expression. J Immunol 2009,
182:4994-5002.
89. Mattes J, Collison A, Plank M, Phipps S, Foster PS: Antagonism of
microRNA-126 suppresses the effector function of TH2 cells and the
development of allergic airways disease. Proc Natl Acad Sci USA 2009,
106:18704-18709.
90. Zhai Y, Zhong Z, Chen CY, Xia Z, Song L, Blackburn MR, Shyu AB:
Coordinated changes in mRNA turnover, translation, and RNA
processing bodies in bronchial epithelial cells following inflammatory
stimulation. Mol Cell Biol 2008, 28:7414-7426.
91. Polikepahad S, Knight JM, Naghavi AO, Oplt T, Creighton CJ, Shaw C,
Benham AL, Kim J, Soibam B, Harris RA, Coarfa C, Zariff A, Milosavljevic A,
Batts LM, Kheradmand F, Gunaratne PH, Corry DB: Pro-inflammatory role
for let-7 microRNAs in experimental asthma. J Biol Chem 2010,
285:30139-30149.
Tomankova et al. Respiratory Research 2010, 11:159
http://respiratory-research.com/content/11/1/159
Page 9 of 1092. Chiba Y, Tanabe M, Goto K, Sakai H, Misawa M: Down-regulation of miR-
133a contributes to up-regulation of Rhoa in bronchial smooth muscle
cells. Am J Respir Crit Care Med 2009, 180:713-719.
93. Chiba Y, Misawa M: MicroRNAs and Their Therapeutic Potential for
Human Diseases: MiR-133a and Bronchial Smooth Muscle
Hyperresponsiveness in Asthma. J Pharmacol Sci 2010, 114:264-268.
94. Caramori G, Casolari P, Cavallesco GN, Giuffrè S, Adcock I, Papi A:
Mechanisms involved in lung cancer development in COPD. Int J
Biochem Cell Biol .
95. Sato T, Liu X, Nelson A, Nakanishi M, Kanaji N, Wang X, Kim M, Li Y, Sun J,
Michalski J, Patil A, Basma H, Holz O, Magnussen H, Rennard SI: Reduced
MiR-146a Increases Prostaglandin E2 in Chronic Obstructive Pulmonary
Disease Fibroblasts. Am J Respir Crit Care Med 2010, 182:1020-1029.
96. Izzotti A, Calin GA, Arrigo P, Steele VE, Croce CM, De Flora S:
Downregulation of microRNA expression in the lungs of rats exposed to
cigarette smoke. FASEB J 2009, 23:806-812.
97. Schembri F, Sridhar S, Perdomo C, Gustafson AM, Zhang X, Ergun A, Lu J,
Liu G, Zhang X, Bowers J, Vaziri C, Ott K, Sensinger K, Collins JJ, Brody JS,
Getts R, Lenburg ME, Spira A: MicroRNAs as modulators of smoking-
induced gene expression changes in human airway epithelium. Proc Natl
Acad Sci USA 2009, 106:2319-2324.
98. Davidson MR, Larsen JE, Yang IA, Hayward NK, Clarke BE, Duhig EE,
Passmore LH, Bowman RV, Fong KM: MicroRNA-218 is deleted and
downregulated in lung squamous cell carcinoma. PLoS One 2010, 5:
e12560.
99. Yanaihara N, Caplen N, Bowman E, Seike M, Kumamoto K, Yi M,
Stephens RM, Okamoto A, Yokota J, Tanaka T, Calin GA, Liu CG, Croce CM,
Harris CC: Unique microRNA molecular profiles in lung cancer diagnosis
and prognosis. Cancer Cell 2006, 9:189-98.
100. Takamizawa J, Konishi H, Yanagisawa K, Tomida S, Osada H, Endoh H,
Harano T, Yatabe Y, Nagino M, Nimura Y, Mitsudomi T, Takahashi T:
Reduced expression of the let-7 microRNAs in human lung cancers in
association with shortened postoperative survival. Cancer Res 2004,
64:3753-3756.
101. Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A,
Labourier E, Reinert KL, Brown D, Slack FJ: RAS is regulated by the let-7
microRNA family. Cell 2005, 120:635-647.
102. Hayashita Y, Osada H, Tatematsu Y, Yamada H, Yanagisawa K, Tomida S,
Yatabe Y, Kawahara K, Sekido Y, Takahashi T: A polycistronic microRNA
cluster, miR-17-92, is overexpressed in human lung cancers and
enhances cell proliferation. Cancer Res 2005, 65:9628-9632.
103. Lu Z, Liu M, Stribinskis V, Klinge CM, Ramos KS, Colburn NH, Li Y:
MicroRNA-21 promotes cell transformation by targeting the
programmed cell death 4 gene. Oncogene 2008, 27:4373-4379.
104. He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y, Xue W, Zender L,
Magnus J, Ridzon D, Jackson AL, Linsley PS, Chen C, Lowe SW, Cleary MA,
Hannon GJ: A microRNA component of the p53 tumour suppressor
network. Nature 2007, 447:1130-1134.
105. Tarasov V, Jung P, Verdoodt B, Lodygin D, Epanchintsev A, Menssen A,
Meister G, Hermeking H: Differential regulation of microRNAs by p53
revealed by massively parallel sequencing: miR-34a is a p53 target that
induces apoptosis and G1-arrest. Cell Cycle 2007, 6:1586-1593.
106. Hermeking H: The miR-34 family in cancer and apoptosis. Cell Death Differ
2010, 17:193-199.
107. Du L, Pertsemlidis A: microRNAs and lung cancer: tumors and 22-mers.
Cancer Metastasis Rev 2010, 29:109-122.
108. Puisségur MP, Mazure NM, Bertero T, Pradelli L, Grosso S, Robbe-
Sermesant K, Maurin T, Lebrigand K, Cardinaud B, Hofman V, Fourre S,
Magnone V, Ricci JE, Pouysségur J, Gounon P, Hofman P, Barbry P, Mari B:
miR-210 is overexpressed in late stages of lung cancer and mediates
mitochondrial alterations associated with modulation of HIF-1 activity.
Cell Death Differ .
109. Pandit KV, Corcoran D, Yousef H, Yarlagadda M, Tzouvelekis A, Gibson KF,
Konishi K, Yousem SA, Singh M, Handley D, Richards T, Selman M,
Watkins SC, Pardo A, Ben-Yehudah A, Bouros D, Eickelberg O, Ray P,
Benos PV, Kaminski N: Inhibition and Role of let-7 d in Idiopathic
Pulmonary Fibrosis. Am J Respir Crit Care Med 2010, 182:220-229.
110. Liu G, Friggeri A, Yang Y, Milosevic J, Ding Q, Thannickal VJ, Kaminski N,
Abraham E: miR-21 mediates fibrogenic activation of pulmonary
fibroblasts and lung fibrosis. J Exp Med 2010, 207:1589-1597.
111. Oglesby IK, Bray IM, Chotirmall SH, Stallings RL, O’Neill SJ, McElvaney NG,
Greene CM: miR-126 is downregulated in cystic fibrosis airway epithelial
cells and regulates TOM1 expression. J Immunol 2010, 184:1702-1709.
112. Giglio S, Vecchione A: Role of microRNAs in the molecular diagnosis of
cancer. Journal of Nucleic Acids Investigation 2010, 1:e4.
113. Nana-Sinkam SP, Karsies T, Riscili B, Ezzie M, Piper M: Lung microRNA: from
development to disease. Expert Rev Respir Med 2009, 3:373-385.
114. Kota J, Chivukula RR, O’Donnell KA, Wentzel EA, Montgomery CL,
Hwang HW, Chang TC, Vivekanandan P, Torbenson M, Clark KR, Mendell JR,
Mendell JT: Therapeutic microRNA delivery suppresses tumorigenesis in
a murine liver cancer model. Cell 2009, 137:1005-1017.
doi:10.1186/1465-9921-11-159
Cite this article as: Tomankova et al.: Involvement of microRNAs in
physiological and pathological processes in the lung. Respiratory
Research 2010 11:159.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tomankova et al. Respiratory Research 2010, 11:159
http://respiratory-research.com/content/11/1/159
Page 10 of 10